Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
Latest Information Update: 05 Oct 2023
At a glance
- Drugs Alpelisib (Primary) ; Dapagliflozin (Primary) ; Fulvestrant (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Adverse reactions
- 02 Sep 2021 New trial record
- 27 Aug 2021 Status changed from not yet recruiting to recruiting.